Special Issue "Finding Anti-mycobacterial Peptides and Inhibitors of Immune Responses for Tuberculosis Therapy"
A special issue of Pathogens (ISSN 2076-0817).
Deadline for manuscript submissions: closed (31 March 2020).
Interests: Infectious Medicine; tuberculosis; peptide; immunomodulator
Despite the availability of antibiotics, tuberculosis (TB) remains a major health concern with an estimated nine million new clinically diagnosed cases per year. Isoniazid and rifampicin form an essential part of the standard four-drug treatment for drug-sensitive infections. The treatment is long, varying from six months for drug-susceptible TB, to more than two years for multi-drug resistant (MDR-TB) strains and extensively drug-resistant (XDR) infections. As the leading infectious cause of death worldwide, TB demands novel approaches that will realistically enable the disease’s elimination. There is a pressing clinical need for the development of new drugs and new drug combinations to treat this infection.
Antimicrobial peptides (AMPs) have attracted interest as potential alternative therapeutic strategies to treat mycobacterial infections. Immunomodulatory agents (IMiDs) are another interesting aspect of future TB therapy. These molecules aim to directly reduce inflammation, thereby preventing lung damage and potentially enhancing the effectiveness of chemotherapy.
For this Special Issue, we invite research studies with the potential to inform clinical practice or open new avenues of clinical research, with a focus on the following:
- Finding AMPs for tuberculosis disease and infection, including drug–drug interaction studies and translational research evaluating novel drugs and drug combinations.
- Identify IMiDs to dampen inflammation during tuberculosis infection and/or to enhance effectiveness to therapy.
Dr. Gabriela Godaly
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Mycobacterium tuberculosis
- antimicrobial peptides
- inhibitors of immune responses
- immunomodulatory agents